These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 34768018)
81. Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice. Uchida T; Imamura M; Hayes CN; Hiraga N; Kan H; Tsuge M; Abe-Chayama H; Zhang Y; Makokha GN; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696237 [TBL] [Abstract][Full Text] [Related]
82. Prophylaxis against hepatitis B virus recurrence after liver transplantation: a registry study. Shen S; Jiang L; Xiao GQ; Yan LN; Yang JY; Wen TF; Li B; Wang WT; Xu MQ; Wei YG World J Gastroenterol; 2015 Jan; 21(2):584-92. PubMed ID: 25593480 [TBL] [Abstract][Full Text] [Related]
83. Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes A to J. Liu CJ; Kao JH Semin Liver Dis; 2013 May; 33(2):97-102. PubMed ID: 23749665 [TBL] [Abstract][Full Text] [Related]
84. Long-term prognosis of liver disease in patients with chronic hepatitis B virus infection receiving nucleos(t)ide analogue therapy: an analysis using a Markov chain model. Tada T; Toyoda H; Yasuda S; Miyake N; Kumada T; Kurisu A; Ohisa M; Akita T; Tanaka J Eur J Gastroenterol Hepatol; 2019 Nov; 31(11):1452-1459. PubMed ID: 31082998 [TBL] [Abstract][Full Text] [Related]
85. Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study. Chang Y; Choe WH; Sinn DH; Lee JH; Ahn SH; Lee H; Shim JJ; Jun DW; Park SY; Nam JY; Cho EJ; Yu SJ; Lee DH; Lee JM; Kim YJ; Kwon SY; Paik SW; Yoon JH J Infect Dis; 2017 Dec; 216(11):1407-1414. PubMed ID: 29029102 [TBL] [Abstract][Full Text] [Related]
86. Relative Abundance of Integrant-Derived Viral RNAs in Infected Tissues Harvested from Chronic Hepatitis B Virus Carriers. Freitas N; Lukash T; Gunewardena S; Chappell B; Slagle BL; Gudima SO J Virol; 2018 May; 92(10):. PubMed ID: 29491161 [TBL] [Abstract][Full Text] [Related]
87. The Yin and the Yang of Treatment for Chronic Hepatitis B-When to Start, When to Stop Nucleos(t)ide Analogue Therapy. Hall S; Howell J; Visvanathan K; Thompson A Viruses; 2020 Aug; 12(9):. PubMed ID: 32854335 [TBL] [Abstract][Full Text] [Related]
88. Novel Biomarkers of Hepatitis B Virus and Their Use in Chronic Hepatitis B Patient Management. Vachon A; Osiowy C Viruses; 2021 May; 13(6):. PubMed ID: 34064049 [TBL] [Abstract][Full Text] [Related]
90. Evaluation of HBV serological markers in treatment-naïve HBV mono-infected patients and HBV-HIV co-infected patients. Jiang B; Su R; Ren D; Zheng X; Cao Y; Mi Y; Wang F; Ma P Virus Res; 2020 Dec; 290():198117. PubMed ID: 32800804 [TBL] [Abstract][Full Text] [Related]
91. New Markers in Monitoring the Reactivation of Hepatitis B Virus Infection in Immunocompromised Hosts. Svicher V; Salpini R; Malagnino V; Piermatteo L; Alkhatib M; Cerva C; Sarmati L Viruses; 2019 Aug; 11(9):. PubMed ID: 31450680 [TBL] [Abstract][Full Text] [Related]
92. Quantification of hepatitis B surface antigen: a new concept for the management of chronic hepatitis B. Moucari R; Marcellin P Liver Int; 2011 Jan; 31 Suppl 1():122-8. PubMed ID: 21205149 [TBL] [Abstract][Full Text] [Related]
93. Novel viral markers and the prediction of off-treatment relapse in chronic hepatitis B patients: A systematic review. Jaroenlapnopparat A; Chayanupatkul M; Tangkijvanich P J Gastroenterol Hepatol; 2021 Sep; 36(9):2349-2362. PubMed ID: 33811375 [TBL] [Abstract][Full Text] [Related]
94. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Reijnders JG; Perquin MJ; Zhang N; Hansen BE; Janssen HL Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492 [TBL] [Abstract][Full Text] [Related]
95. Cross-sectional evaluation of circulating hepatitis B virus RNA and DNA: Different quasispecies? Garcia-Garcia S; Cortese MF; Tabernero D; Gregori J; Vila M; Pacín B; Quer J; Casillas R; Castillo-Ribelles L; Ferrer-Costa R; Rando-Segura A; Trejo-Zahínos J; Pumarola T; Casis E; Esteban R; Riveiro-Barciela M; Buti M; Rodríguez-Frías F World J Gastroenterol; 2021 Nov; 27(41):7144-7158. PubMed ID: 34887634 [TBL] [Abstract][Full Text] [Related]
96. [Prophylactic Antiviral Treatment in Immunosuppressed Chronic Hepatitis B Patients]. Yoon EL Korean J Gastroenterol; 2019 Nov; 74(5):258-266. PubMed ID: 31765554 [TBL] [Abstract][Full Text] [Related]
97. Combined viral quasispecies diversity and hepatitis B core-related antigen predict off-nucleos(t)ide analog durability in HBeAg-negative patients. Cheng HR; Yang HC; Lin SR; Yang TY; Lin YY; Su TH; Tseng TC; Liu CJ; Kao JH Hepatol Int; 2021 Jun; 15(3):582-592. PubMed ID: 33886088 [TBL] [Abstract][Full Text] [Related]
98. The efficacy and safety of nucleos(t)ide analogues in the treatment of HBV-related acute-on-chronic liver failure: a meta-analysis. Yu S; Jianqin H; Wei W; Jianrong H; Yida Y; Jifang S; Liang Y; Zhi C; Hongyu J Ann Hepatol; 2013; 12(3):364-72. PubMed ID: 23619252 [TBL] [Abstract][Full Text] [Related]
99. Treatment of chronic hepatitis B: Evolution over two decades. Yuen MF; Lai CL J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525 [TBL] [Abstract][Full Text] [Related]
100. Immunopathogenesis of Hepatitis B Virus. Tseng TC; Huang LR J Infect Dis; 2017 Nov; 216(suppl_8):S765-S770. PubMed ID: 29156047 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]